MiniMed Group (NASDAQ:MMED) Now Covered by Analysts at The Goldman Sachs Group

The Goldman Sachs Group assumed coverage on shares of MiniMed Group (NASDAQ:MMED) in a research report released on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $24.00 price objective on the stock.

Several other analysts have also issued reports on the stock. Wells Fargo & Company initiated coverage on shares of MiniMed Group in a research report on Tuesday. They issued an “overweight” rating and a $26.00 price target on the stock. William Blair started coverage on shares of MiniMed Group in a research note on Tuesday. They issued an “outperform” rating for the company. Evercore began coverage on shares of MiniMed Group in a report on Tuesday. They set an “outperform” rating and a $20.00 target price on the stock. Mizuho began coverage on MiniMed Group in a research report on Tuesday. They set an “outperform” rating and a $21.00 target price on the stock. Finally, Piper Sandler began coverage on MiniMed Group in a research report on Tuesday. They issued a “neutral” rating and a $16.00 price target for the company. Ten research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.10.

MiniMed Group Trading Up 4.0%

NASDAQ MMED opened at $14.92 on Tuesday. MiniMed Group has a 52 week low of $14.10 and a 52 week high of $20.48.

Trending Headlines about MiniMed Group

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Multiple major brokerages initiated coverage with bullish ratings and high price targets, supporting upside expectations — notable examples include Bank of America ($27 PT) and Goldman Sachs ($24 PT). This broad coverage is being read as validation of MMED’s standalone pipeline and commercial opportunity. MiniMed initiated with ‘Buy’ rating by Bank of America on pipeline-driven growth outlook
• Positive Sentiment: Other buy/overweight/outperform starts include Wells Fargo ($26), BTIG ($25), Citigroup ($23), Mizuho ($21), Evercore ($20), Deutsche Bank ($20) and Morgan Stanley ($19) — analyst price targets span roughly $16–$27, implying material upside from recent levels and giving investors multiple bullish third‑party valuations. Coverage roundup
• Neutral Sentiment: Piper Sandler placed a neutral/”neutral” stance with a $16 price target — this is less bullish than many peers and may moderate expectations for near‑term re‑rating. Piper Sandler coverage note
• Negative Sentiment: Analysts who stayed cautious (Piper Sandler / coverage summarized on TipRanks) cite execution risks as a reason for a Hold/neutral view; those execution concerns could cap upside if the company misses early standalone milestones. Balancing Franchise Strength with Execution Risks: Why MiniMed Merits a Hold Rating

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.